ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: According to the Hungarian National Institute of Pharmacy and Nutrition database, the first two targeted therapeutic agents were trastuzumab for Her2-positive breast cancer, and imatinib for bcr-abl-positive chronic myeloid leukaemia, which were approved in 2000 and 2001, respectively [12].